EZH2 and neoplasm: It was subsequently advanced to phase II for patients with advanced solid tumours or with B-cell lymphomas.211 In patients with follicular lymphoma, it showed an objective response rate in 69% of patients with EZH2 mutant tumours and 35% with EZH2 WT tumours, suggesting its use as a treatment for follicular lymphoma.